dapoxetine

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Erectile Dysfunction

Conditions

Erectile Dysfunction

Trial Timeline

Dec 1, 2004 → Oct 1, 2006

NCT ID

NCT00229073

About dapoxetine

dapoxetine is a phase 3 stage product being developed by Johnson & Johnson for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00229073. Target conditions include Erectile Dysfunction.

What happened to similar drugs?

12 of 20 similar drugs in Erectile Dysfunction were approved

Approved (12) Terminated (0) Active (8)

🔄tadalafil + placeboEli LillyPhase 3

✅Tacrolimus + PlaceboAstellas PharmaApproved

🔄tadalafil + placeboEli LillyPhase 3

🔄tadalafilEli LillyPhase 3

✅TadalafilEli LillyApproved

✅tadalafil + placeboEli LillyApproved

✅Tadalafil + Sildenafil CitrateEli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00210704	Phase 3	Completed	Mar 1, 2005	Jun 1, 2006	Erectile Dysfunction
NCT00229073	Phase 3	Completed	Dec 1, 2004	Oct 1, 2006	Erectile Dysfunction
NCT00210613	Phase 3	Completed	Nov 1, 2004	Aug 1, 2005	Sexual Dysfunction

Competing Products

20 competing products in Erectile Dysfunction

See all competitors

Product	Company	Stage	Hype Score
tadalafil + placebo	Eli Lilly	Phase 3	40
YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo	Yuhan	Phase 2	35
Tacrolimus + Placebo	Astellas Pharma	Approved	43
Mirabegron	Astellas Pharma	Phase 1/2	32
LY2452473 + Tadalafil + LY900010	Eli Lilly	Phase 1	29
tadalafil + placebo	Eli Lilly	Phase 3	40
tadalafil	Eli Lilly	Phase 3	40
LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473)	Eli Lilly	Phase 2	35
Tadalafil	Eli Lilly	Approved	43
tadalafil + placebo	Eli Lilly	Approved	43
Tadalafil + Sildenafil Citrate	Eli Lilly	Approved	43
Tadalafil + Placebo	Eli Lilly	Phase 3	40
Placebo + Tadalafil	Eli Lilly	Approved	43
Tadalafil + Placebo	Eli Lilly	Approved	43
tadalafil	Eli Lilly	Approved	43
Tadalafil + Sildenafil	Eli Lilly	Approved	43
tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)]	Eli Lilly	Phase 3	40
Tadalafil + Placebo	Eli Lilly	Approved	43
Dapoxetine	Johnson & Johnson	Phase 3	40
Placebo + Dapoxetine + PDE5I (phosphodiesterase-5 inhibitor)	Johnson & Johnson	Phase 3	40